DNA testing is getting more popular, and interest in investing in genetics is trending up as well. While a lot of the most popular names in home DNA test kits, like 23andme and Ancestry, aren't yet publicly traded, there are still plenty of companies that let you invest on the trend. There are also new IPOs in this field, with via a merger with VG Acquisition (VGAC).
The best genetic testing stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.
The top genetic testing stocks included on this page all trade on the S&P 500, have an analyst recommendation of "Buy" or better and are sorted by year-to-date performance.
Natera, Inc. , a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Natera stock opened the day at $166.98 after a previous close of $165.34. The latest price was $167.55 (25-minute delay). Natera is listed on the NASDAQ, has a trailing 12-month revenue of around USD1.8 billion and employs 4,424 staff.
Genetic Technologies Limited, a molecular diagnostics company, engages in the provision of predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company operates through EasyDNA, AffinityDNA, and GeneType/Corporate segments. It offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer.
Genetic Technologies stock opened the day at $0.77 after a previous close of $0.77. The latest price was $0.77 (25-minute delay). Genetic Technologies is listed on the NASDAQ, has a trailing 12-month revenue of around USD$9.7 million and employs 55 staff.
VG Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
VG Acquisition stock opened the day at $0.00 after a previous close of $0.00. The latest price was $0.00 (25-minute delay). VG Acquisition is listed on the NYSE.
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.
Sangamo Therapeutics stock opened the day at $0.50 after a previous close of $0.49. The latest price was $0.48 (25-minute delay). Sangamo Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$63.8 million and employs 183 staff.
Check out Finder's picks for the best brokerage accounts
Compare top brokerage accounts and apps to help you maximize your investment.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
We review the Kalshi trading platform and explain how investors can use it as a hedge for their investments.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Compare pros, cons, research tools and reviews for these two trading platforms.
Fractional shares are fractions of company shares. Sometimes they’re made by brokers to allow those with limited funds to get access to stocks.
SoFi Invest is a no-fee commissions platform with both active and automated investment accounts.
Webull is a broker with zero-commission trading and a suite of tools to help you invest.